Characteristics of Real-World Patients with High-Risk BRAFV600E/K-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program

Characteristics of Real-World Patients with High-Risk BRAFV600E/K-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program

Pietro Quaglino,1 Paolo A Ascierto,2 Francesca Consoli,3 Paola Queirolo,4 Francesco Spagnolo,5 Maria Francesca Morelli,6 Rossana Berardi,7 Vanna Chiarion-Sileni,8 Marco Tucci,9 Teresa Troiani,10 Barbara Melotti,11 Ernesto Rossi,12 Mario Mandala,13 Gaetana Rinaldi,14 Ilaria Gioia Marcon,15 Matteo Piz...

Full description

Bibliographic Details
Main Authors: Quaglino P, Ascierto PA, Consoli F, Queirolo P, Spagnolo F, Morelli MF, Berardi R, Chiarion-Sileni V, Tucci M, Troiani T, Melotti B, Rossi E, Mandala M, Rinaldi G, Marcon IG, Pizzuti M, Del Vecchio M
Format: Article
Language:English
Published: Dove Medical Press 2023-11-01
Series:Cancer Management and Research
Subjects:
braf mutation
dabrafenib
melanoma
real-world
trametinib
managed access program
Online Access:https://www.dovepress.com/characteristics-of-real-world-patients-with-high-risk-brafv600ek-mutat-peer-reviewed-fulltext-article-CMAR

Internet

https://www.dovepress.com/characteristics-of-real-world-patients-with-high-risk-brafv600ek-mutat-peer-reviewed-fulltext-article-CMAR

Similar Items